Pepper Bio

About Pepper Bio

Pepper develops advanced bioinformatics tools for genomic data analysis and interpretation. The platform streamlines complex sequencing workflows, enabling researchers to efficiently process and visualize large-scale biological datasets. This technology accelerates discovery in areas like precision medicine and functional genomics.

```xml <problem> Current drug discovery processes for aggressive cancers and other complex conditions often fail to identify effective treatments due to an incomplete understanding of the underlying biological mechanisms and patient-specific responses. Traditional methods struggle to integrate the vast amounts of omic data needed to reveal actionable insights for novel drug development and patient stratification. </problem> <solution> Pepper Bio offers a transomic platform that integrates phosphoproteomics, proteomics, transcriptomics, and genomics data to provide a comprehensive understanding of disease biology and drug mechanisms. The platform, called COMPASS, leverages machine learning to analyze a proprietary transomics database, identifying new drug targets and predicting patient responses for previously untreatable diseases. By capturing global, functional, and causative data, Pepper Bio's approach aims to accelerate drug discovery, enable patient stratification, and unlock greater commercial opportunities through biomarker and target identification, indication expansion, drug combinations, and lead optimization. The company is currently developing novel drug programs, including four in current development, and partners with R&D teams to advance their business. </solution> <features> - Integrates phosphoproteomics, proteomics, transcriptomics, and genomics data for a comprehensive view of disease biology. - Machine learning-driven platform (COMPASS) identifies new drug targets and predicts patient responses. - Proprietary transomics database built from pre-clinical discovery in untreatable cancers. - Identifies biomarkers for patient stratification and indication expansion. - Facilitates target identification and lead optimization for drug development. - Supports drug combination strategies. - Aims to provide an end-to-end, repeatable drug development process. </features> <target_audience> Pepper Bio's primary customers are pharmaceutical and biotech companies, as well as R&D teams, seeking to improve their drug discovery process, identify new drug targets, and develop effective treatments for aggressive cancers and other complex conditions. </target_audience> ```

What does Pepper Bio do?

Pepper develops advanced bioinformatics tools for genomic data analysis and interpretation. The platform streamlines complex sequencing workflows, enabling researchers to efficiently process and visualize large-scale biological datasets. This technology accelerates discovery in areas like precision medicine and functional genomics.

Where is Pepper Bio located?

Pepper Bio is based in Boston, United States.

How much funding has Pepper Bio raised?

Pepper Bio has raised $11.3M.

Location
Boston, United States
Funding
$11.3M
Employees
8 employees
Investors
NFXBertelsmann InvestmentsBigbetsDenver VenturesEic.Capital Enrissionindia.JpKbj CapitalQ VenturesSevenexSifr

Pepper Bio

Executive Summary

Pepper develops advanced bioinformatics tools for genomic data analysis and interpretation. The platform streamlines complex sequencing workflows, enabling researchers to efficiently process and visualize large-scale biological datasets. This technology accelerates discovery in areas like precision medicine and functional genomics.

pepper.bio1K+
Boston, United States

Funding

No specific funding rounds found.

Total Funding

$11.3M

Backed by

Bertelsmann InvestmentsBigbetsDenver VenturesEic.Capital Enrissionindia.JpKbj Capital…

Team (5+)

No team information available.

Company Description

Problem

Current drug discovery processes for aggressive cancers and other complex conditions often fail to identify effective treatments due to an incomplete understanding of the underlying biological mechanisms and patient-specific responses. Traditional methods struggle to integrate the vast amounts of omic data needed to reveal actionable insights for novel drug development and patient stratification.

Solution

Pepper Bio offers a transomic platform that integrates phosphoproteomics, proteomics, transcriptomics, and genomics data to provide a comprehensive understanding of disease biology and drug mechanisms. The platform, called COMPASS, leverages machine learning to analyze a proprietary transomics database, identifying new drug targets and predicting patient responses for previously untreatable diseases. By capturing global, functional, and causative data, Pepper Bio's approach aims to accelerate drug discovery, enable patient stratification, and unlock greater commercial opportunities through biomarker and target identification, indication expansion, drug combinations, and lead optimization. The company is currently developing novel drug programs, including four in current development, and partners with R&D teams to advance their business.

Features

Integrates phosphoproteomics, proteomics, transcriptomics, and genomics data for a comprehensive view of disease biology.

Machine learning-driven platform (COMPASS) identifies new drug targets and predicts patient responses.

Proprietary transomics database built from pre-clinical discovery in untreatable cancers.

Identifies biomarkers for patient stratification and indication expansion.

Facilitates target identification and lead optimization for drug development.

Supports drug combination strategies.

Aims to provide an end-to-end, repeatable drug development process.

Target Audience

Pepper Bio's primary customers are pharmaceutical and biotech companies, as well as R&D teams, seeking to improve their drug discovery process, identify new drug targets, and develop effective treatments for aggressive cancers and other complex conditions.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.